Biotech news for Sunday, June 7, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
ADC Therapeutics ( ADCT ) reached a new 52-week low on Thursday as RBC Capital Markets downgraded the stock following topline data from a confirmatory Phase 3 trial for a combination regimen containing its FDA-approved lymphoma therapy Zynlonta. The antibody-d…
Celcuity ( CELC ) priced an upsized $500M offering of 0.250% convertible senior notes due 2032, up from the previously announced $400M. The initial purchasers were granted a 30-day option to buy up to an additional $75M notes. The notes will be
Jade Biosciences ( JBIO ) has announced the pricing of a public offering of 10M shares of its common stock, priced at $15.00 per share, expected to raise gross proceeds of $150M from this offering. The offering will close on June 5, 2026, after meeting
Just_Super Alnylam Pharmaceuticals ( ALNY ) has signed a deal potentially worth up to $2B with Inceptive Nucleics to use generative AI models to accelerate the development of RNAi therapeutics. Inceptive Nucleics will receive $30M upfront, inclusive of cash an…
Jade Biosciences ( JBIO ) on Wednesday said it intends to offer shares of common stock and, in lieu of common stock for certain investors, pre-funded warrants in an underwritten public offering. The company also plans to grant underwriters a 30-day option